Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 21.70 as of 2026-10-06T18:27:40.180Z.
Consensus retrieved: 2026-10-06T14:19:14.851Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:27:40.180Z.
Quote observation: 2026-10-06T18:23:44.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1c729578d7c27396710c0ea90e9ab9204ea73368ecaa5be541092ba03472cb43
Forward PE Ratio (21.70) = Dated Quote Price ($3.40) / Consensus Forward EPS ($0.16)
FORWARD PE RATIO
21.70
SECTOR MEDIAN · HEALTHCARE
19.90
median of 191 covered companies
CURRENT VS SECTOR MEDIAN
+9.05%
vs the sector median at left
Nephros, Inc.
Market Cap
$36.91M
Forward PE Ratio
21.70
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Nephros, Inc. (NEPH) | $36.91M | 21.70 |
| Incannex Healthcare Limited (IXHL)vs › | $37.94M | N/A |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.81M | N/A |
| Metagenomi, Inc. Common Stock (MGX)vs › | $39.06M | N/A |
| Edesa Biotech, Inc. (EDSA)vs › | $36.70M | N/A |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.51M | N/A |
| QT Imaging Holdings, Inc. (QTI)vs › | $36.28M | N/A |
| EUDA Health Holdings Limited (EUDA)vs › | $35.69M | 11.94 |
| DocGo Inc. (DCGO)vs › | $35.57M | N/A |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.50M | N/A |
Trailing P/E
21.4
reported TTM EPS
Forward P/E
21.7
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.16 implies +0.0% EPS growth vs the reported trailing $0.16.
At the dated quote price of $3.40, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.16 | $0.16 – $0.16 | 1 | 21.7x |
| 2027-12-31 | $0.26 | $0.26 – $0.26 | 1 | 13.1x |
| 2028-12-31 | $0.32 | $0.32 – $0.32 | 1 | 10.6x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
